- Home
- NUKK vs OGEN Comparison
NUKK vs OGEN Comparison
Compare NUKK & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- OGEN
- Stock Information
- Founded
- NUKK 2013
- OGEN 1996
- Country
- NUKK United States
- OGEN United States
- Employees
- NUKK N/A
- OGEN N/A
- Industry
- NUKK Blank Checks
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- OGEN Health Care
- Exchange
- NUKK Nasdaq
- OGEN Nasdaq
- Market Cap
- NUKK 4.8M
- OGEN 4.5M
- IPO Year
- NUKK N/A
- OGEN N/A
- Fundamental
- Price
- NUKK $50.79
- OGEN $0.33
- Analyst Decision
- NUKK
- OGEN
- Analyst Count
- NUKK 0
- OGEN 0
- Target Price
- NUKK N/A
- OGEN N/A
- AVG Volume (30 Days)
- NUKK 11.1M
- OGEN 248.5K
- Earning Date
- NUKK 12-31-2024
- OGEN 11-13-2024
- Dividend Yield
- NUKK N/A
- OGEN N/A
- EPS Growth
- NUKK N/A
- OGEN N/A
- EPS
- NUKK N/A
- OGEN N/A
- Revenue
- NUKK $10,752,616.00
- OGEN N/A
- Revenue This Year
- NUKK N/A
- OGEN N/A
- Revenue Next Year
- NUKK N/A
- OGEN N/A
- P/E Ratio
- NUKK N/A
- OGEN N/A
- Revenue Growth
- NUKK N/A
- OGEN N/A
- 52 Week Low
- NUKK $1.30
- OGEN $0.25
- 52 Week High
- NUKK $67.77
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- NUKK 98.34
- OGEN 48.67
- Support Level
- NUKK $1.34
- OGEN $0.32
- Resistance Level
- NUKK $1.60
- OGEN $0.38
- Average True Range (ATR)
- NUKK 4.90
- OGEN 0.03
- MACD
- NUKK 3.54
- OGEN 0.00
- Stochastic Oscillator
- NUKK 74.44
- OGEN 36.00
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically, the majority of its revenue is generated from the United Kingdom and the rest from the United States and Malta.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.